Background Statin therapy prior to percutaneous coronary intervention (PCI) is associated with reduced mortality and the reduction of periprocedural myocardial injury after PCI. We evaluated the effects of single high dose of rosuvastatin loading before PCI.
Methods and Results Consecutive 181 patients with acute coronary syndrome (ACS) who underwent PCI were randomly assigned to either the group of no statin treatment before PCI (Group I: n=90) or the group of 40 mg rosuvastatin loading before PCI (Group II: n=91). Incidence of periprocedural myocardial injury was assessed by analysis of creatinine kinase-MB (CK-MB) and cardiac troponin T before PCI, at 6 hours and the next morning after PCI. There were no significant differences in clinical characteristics between the two groups. After PCI, incidence of periprocedural myocardial injury was higher in Group I than in Group II (p=0.029 in CK-MB >3 times, p=0.042 in troponin T >3 times upper normal limit). In-hospital and 30-day MACE were higher in Group I than in Group II (8.9% vs. 2.2%, p=0.048; 10.0% vs. 2.2%, p=0.028). Multivariate analysis revealed that no prior use of statin, procedural complication and high postprocedural hsCRP level were the independent predictors for periprocedural myocardial injury.
Conclusion Single high dose of rosuvastatin prior to PCI reduces in-hospital and 30 day MACE and periprocedural myocardial injury in patients with ACS.